MS67 exhibited potent growth suppression of AML cells from deidentified patients in vitro and displayed efficacy in an MLL-AF9+ AML PDX-xenograft model, leading to prolonged survival rates without any significant loss of body weight. Here, KMT2A is linked to acute myeloid leukemia.